The potential impact of a new cancer drug, designed to stop patients becoming resistant to common therapies in treating cancer of the lung, ovary, breast, colon and pancreas.
Dr David Houston and Mr James Blaxland (PHRMY), represented Cardiff University at the BBSRC Biotechnology Young Entrepreneurs Scheme regional competition.